MX2019007892A - Compuestos inhibidores de metaloenzimas. - Google Patents

Compuestos inhibidores de metaloenzimas.

Info

Publication number
MX2019007892A
MX2019007892A MX2019007892A MX2019007892A MX2019007892A MX 2019007892 A MX2019007892 A MX 2019007892A MX 2019007892 A MX2019007892 A MX 2019007892A MX 2019007892 A MX2019007892 A MX 2019007892A MX 2019007892 A MX2019007892 A MX 2019007892A
Authority
MX
Mexico
Prior art keywords
inhibitor compounds
metalloenzyme inhibitor
metalloenzyme
compounds
metalloenzymes
Prior art date
Application number
MX2019007892A
Other languages
English (en)
Inventor
sparks Steven
m yates Christopher
R Shaver Sammy
J Hoekstra William
Original Assignee
Selenity Therapeutics Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selenity Therapeutics Bermuda Ltd filed Critical Selenity Therapeutics Bermuda Ltd
Publication of MX2019007892A publication Critical patent/MX2019007892A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proveen compuestos que tienen actividad moduladora de metaloenzimas y métodos de tratamiento de enfermedades, trastornos o síntomas de los mismos mediados por tales metaloenzimas.
MX2019007892A 2016-12-29 2017-12-22 Compuestos inhibidores de metaloenzimas. MX2019007892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662440181P 2016-12-29 2016-12-29
PCT/US2017/068190 WO2018125800A2 (en) 2016-12-29 2017-12-22 Metalloenzyme inhibitor compounds

Publications (1)

Publication Number Publication Date
MX2019007892A true MX2019007892A (es) 2020-02-05

Family

ID=62709109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007892A MX2019007892A (es) 2016-12-29 2017-12-22 Compuestos inhibidores de metaloenzimas.
MX2022012386A MX2022012386A (es) 2016-12-29 2019-06-28 Compuestos inhibidores de metaloenzimas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022012386A MX2022012386A (es) 2016-12-29 2019-06-28 Compuestos inhibidores de metaloenzimas.

Country Status (15)

Country Link
US (3) US10085984B2 (es)
EP (2) EP3562487B1 (es)
JP (2) JP7227157B2 (es)
KR (1) KR20190129034A (es)
CN (1) CN110691598A (es)
AU (1) AU2017387033B2 (es)
BR (1) BR112019013478A2 (es)
CA (1) CA3055292A1 (es)
DK (1) DK3562487T3 (es)
ES (1) ES2967119T3 (es)
FI (1) FI3562487T3 (es)
MX (2) MX2019007892A (es)
RU (1) RU2764666C2 (es)
TW (1) TWI786078B (es)
WO (1) WO2018125800A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2774267T3 (es) * 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US20220081420A1 (en) * 2019-01-08 2022-03-17 Steven Sparks Metalloenzyme inhibitor compounds
GB201901757D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
EP4153566A1 (en) 2020-05-19 2023-03-29 Bayer CropScience Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
CA3186659A1 (en) 2020-06-10 2021-12-16 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
KR101108722B1 (ko) * 2002-01-07 2012-02-17 에자이 알앤드디 매니지먼트 가부시키가이샤 데아자퓨린 및 이의 용도
WO2004082638A2 (en) 2003-03-17 2004-09-30 Syrrx, Inc. Histone deacetylase inhibitors
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
KR101099303B1 (ko) 2005-01-28 2011-12-26 주식회사 대웅제약 신규한 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
MX2009011208A (es) 2007-04-19 2009-10-30 Novartis Ag Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
AU2008267444A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
WO2009045385A1 (en) 2007-10-04 2009-04-09 Merck & Co., Inc. N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors
CA2714370C (en) 2008-02-07 2017-05-02 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
ES2459468T3 (es) 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
EP2501678B1 (en) 2009-11-17 2015-09-23 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
EP2595482A4 (en) * 2010-07-21 2013-12-25 Merck Sharp & Dohme ALDOSTERONSYNTHASEHEMMER
US20130227717A1 (en) 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
US8815854B2 (en) * 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
WO2013033901A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
CN103626783B (zh) * 2012-08-22 2016-06-08 中国科学院上海药物研究所 双环稠杂环化合物及其用途和药物组合物
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
EP3558984B1 (en) 2016-12-20 2023-08-02 FMC Corporation Fungicidal oxadiazoles
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds

Also Published As

Publication number Publication date
US20210322409A1 (en) 2021-10-21
EP3562487A4 (en) 2020-08-26
RU2764666C2 (ru) 2022-01-19
AU2017387033A1 (en) 2019-08-15
EP4311577A2 (en) 2024-01-31
ES2967119T3 (es) 2024-04-26
AU2017387033B2 (en) 2024-02-01
MX2022012386A (es) 2022-11-30
EP4311577A3 (en) 2024-04-17
EP3562487B1 (en) 2023-11-29
DK3562487T3 (da) 2024-01-02
RU2019123854A3 (es) 2021-05-12
KR20190129034A (ko) 2019-11-19
TWI786078B (zh) 2022-12-11
JP7227157B2 (ja) 2023-02-21
US20190008861A1 (en) 2019-01-10
CN110691598A (zh) 2020-01-14
FI3562487T3 (fi) 2023-12-14
US10085984B2 (en) 2018-10-02
BR112019013478A2 (pt) 2020-01-07
CA3055292A1 (en) 2018-07-05
US20180185362A1 (en) 2018-07-05
WO2018125800A3 (en) 2018-08-16
JP2020510693A (ja) 2020-04-09
EP3562487A2 (en) 2019-11-06
US11040034B2 (en) 2021-06-22
TW201831465A (zh) 2018-09-01
JP2023071692A (ja) 2023-05-23
RU2019123854A (ru) 2021-02-01
WO2018125800A2 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
UA114090C2 (uk) Сполуки, що інгібують металоферменти
MX2018016046A (es) Quinazolina y compuestos indol para tratar trastornos medicos.
IN2014DN00286A (es)
IN2014MN00093A (es)
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
IN2014DN06792A (es)
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
BR112017006664A2 (pt) terapias de combinação
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
WO2012058529A3 (en) Metalloenzyme inhibitor compounds
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
EA201890884A1 (ru) Способ и композиции для нежелательных и аномальных мышечных сокращений
NZ740817A (en) Pcna inhibitors